Inovio Pharmaceuticals Files 8-K with Financial Updates

Ticker: INO · Form: 8-K · Filed: Aug 8, 2024 · CIK: 1055726

Inovio Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyInovio Pharmaceuticals, INC. (INO)
Form Type8-K
Filed DateAug 8, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financial-results, sec-filing, operations

Related Tickers: INO

TL;DR

INOVIO just dropped its 8-K with financials – check it out!

AI Summary

On August 8, 2024, Inovio Pharmaceuticals, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits, providing an update on the company's performance.

Why It Matters

This filing provides investors with crucial, up-to-date financial information and operational details for Inovio Pharmaceuticals, Inc.

Risk Assessment

Risk Level: medium — 8-K filings are standard disclosures, but the specific financial details within can reveal significant company performance and future outlook.

Key Players & Entities

FAQ

What specific financial statements are included in this 8-K filing?

The filing indicates that 'Financial Statements and Exhibits' are included, but the specific details of these statements are not provided in the excerpt.

What is the primary purpose of this 8-K filing for Inovio Pharmaceuticals, Inc.?

The primary purpose is to report on 'Results of Operations and Financial Condition' and to file 'Financial Statements and Exhibits'.

When was Inovio Pharmaceuticals, Inc. incorporated?

The company was incorporated in Delaware.

What is the SIC code for Inovio Pharmaceuticals, Inc.?

The Standard Industrial Classification (SIC) code is 3841, which corresponds to 'SURGICAL & MEDICAL INSTRUMENTS & APPARATUS'.

What were the previous names of Inovio Pharmaceuticals, Inc.?

Previous names include INOVIO BIOMEDICAL CORP, GENETRONICS BIOMEDICAL CORP, and GENETRONICS BIOMEDICAL LTD.

Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-08-08 17:00:54

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number 99.1 Press Release, dated August 8, 2024 104 Cover Page Interactive Data File (formatted as inline XBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INOVIO PHARMACEUTICALS, INC. Date: August 8, 2024 By: /s/ Peter Kies Peter Kies Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing